PMX-622 (polymyxin B-dextran 70) does not alter in vitro activities of 11 antimicrobial agents.
Because of its capacity to neutralize the lethality of gram-negative bacterial endotoxic lipopolysaccharides, PMX-622 (polymyxin B bound to dextran 70) is being developed for possible adjunctive therapy of gram-negative sepsis. In this study, it was determined that the in vitro antimicrobial activity of PMX-622 was minimal and that it does not interfere with the in vitro antimicrobial activity of 11 antibiotics commonly used to treat gram-negative infections.
The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA. cmi@hevanet.com
P C
PC
Fuchs
A L
AL
Barry
S D
SD
Brown
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003911:Dextrans / Q000008:administration & dosage*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D011112:Polymyxin B / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D003911:Dextrans; D011112:Polymyxin B